
The Centre offers:

BII was established in July 2001 to train manpower and build capabilities in bioinformatics. BII's research focus centres around knowledge discovery from biological data, exploiting high-end computing in biomedicine, advancing molecular imaging of biological processes, modelling of drug design and delivery, computational proteomics and systems biology.
Go to BII
The mission of the Bioprocessing Technology Institute (BTI) is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocess community. Spearheading bioprocess R&D, the BTI has core expertise in expression engineering, animal cell technology, stem cells, microbial fermentation, product characterisation, downstream processing, purification and stability, with supporting proteomics and microarray platform technologies. BTI, with its R&D and its cGMP manufacturing capabilities, bridges the gaps between discovery, process development and commercialisation.
Go to BTI
Research undertaken by DSI include:

Established in June 2000 as the Singapore Genomics Program, the renamed Genome Institute of Singapore (GIS) is a national flagship initiative with a global vision that seeks to use genomic sciences to improve public health and prosperity.
As a centre for genomic discovery, GIS pursues the integration of technology, genetics, and biology towards the goal of individualised medicine. The scientific focus will be to investigate post-sequence genomics; to understand the genetic architecture of pan-Asian populations with emphasis on cancer biology, pharmacogenomics, stem cell biology and infectious diseases. The genomics infrastructure at GIS will be utilized to train new scientific talent, to function as a bridge for academic and industrial research and explore scientific questions of high impact.
Dr Edison Liu, former Director of the National Cancer Institute's Division of Clinical Sciences in the U.S.A., heads the GIS as the Executive Director.

I2R performs R&D in information, communications and media (ICM) technologies to develop holistic solutions across the ICM value chain. Our research capabilities are in information technology and science, wireless and optical communications, and interactive digital media.
The following are our research departments and programs:
Departments:
Programmes:

Bioengineering and nanotechnology represent two frontiers in engineering. They are both multidisciplinary in nature and highly diverse in scope. The Institute of Bioengineering and Nanotechnology (IBN) was founded in 2002 to conduct research at the cutting-edge of these two fields by focusing on the enormous opportunities that are presented at the interface of these emerging technologies.
Specifically, IBN researchers are directing their efforts towards six research areas that are both scientifically exciting and full of potential towards improving our health and quality of life. These include: nanobiotechnology, delivery of drugs, proteins and genes, tissue engineering, artificial organs and implants, medical devices, and biological and biomedical imaging. IBN's target is to create a critical knowledge base in bioengineering and nanotechnology, and to make a significant impact through the generation of new materials, devices, instruments, systems and processes. We are creating technology platforms that will lead to the development of novel products and the growth of new industries through technology licensing, transfer and spin-off.
By fostering a creative, collaborative and resourceful research environment, IBN seeks to establish a world-class and vibrant research institute that attracts international talents and our best young scientists to conduct research in bioengineering and nanotechnology.

Research undertaken by ICES include:

Research undertaken by IHPC include:

Research undertaken by IMRE include:

The Institute of Medical Biology (IMB) has a strategic, programme-directed portfolio of research focused on issues at the critical interface between basic science and medicine. The aim is to facilitate the development of translational research by building bridges between clinical and basic science. IMB is currently hosting research programmes concerned with different aspects of human disease.
The current programmes within IMB are the Singapore Onco-Genome project, Regenerative Medicine, Papillomavirology, Epithelial Biology and the Lab of Stem Cell Biology from Singapore Stem Cell Consortium (SSCC). The Institute of Medical Biology will help scientists and clinicians to work closely together to support, inform and refine each other’s strengths and specializations to increase the efficiency of the translation process, and ultimately contribute towards a better quality of life for all.
Go to IMB
Recent R&D efforts include:

The Institute of Molecular and Cell Biology (IMCB) was established in 1987 to help develop and support biomedical R&D capabilities in Singapore. Currently the institute has 34 independent research groups with more than 400 staff members.
Today, IMCB has established itself as a world-class research institute in biomedical sciences with core strengths in cell cycling, cell signaling, cell death, cell motility and protein trafficking. Its recent achievements include being part of an international consortium which successfully sequenced the entire pufferfish (Fugu) genome - a world first. IMCB was awarded the Nikkei Prize 2000 for Technological Innovation in recognition of its growth into a leading international research centre and its collaboration with industry and research institutes world-wide.
The Singapore Institute for Clinical Sciences (SICS) will accelerate the translation of basic discoveries into new diagnostics and therapeutics. SICS will be distinguished by its focus on clinical science and the use of innovative approaches and technologies that enable the efficient and effective study of human health and disease. In so doing, the institute will attract, train and nurture a new type of clinician scientist. SICS will collaborate with universities, research institutes and clinical programs to achieve the ultimate goal of improving human health as well as Singapore’s economic well-being.
The research focus of SICS will be centered on the human as the model system, and will complement other A*STAR Research Institutes by focusing on the clinical and translational research portion of the spectrum of biomedical research. SICS will have both intramural research programs and extramural outreach initiatives.
Intramural Programs are focused on specific disease areas. The initial programs at SICS are Genetic Medicine, Hepatic Infectious Diseases andMetabolic Diseases. SICS participates in, or provides oversight to programs external to our institute through our Extramural Programs: Lilly-NUS/SICS Joint Fellowship, Metabolic Interest Group, Supporting the National Medical Research Council in coordinating the STaR Investigatorship Awards and Translational and Clinical Research Flagship Awards